Gram-Negative Bacterial Infections After Hematopoietic Stem Cell or Solid Organ Transplantation

  • Diana Averbuch
  • Dan Engelhard


Reemergence of gram-negative rods (GNR) is reported in hematopoietic stem cell (HSCT) and solid organ transplant recipients (SOTR). The main GNR are Enterobacteriaceae, followed by Pseudomonas aeruginosa; other more rare non-fermentative GNR include Acinetobacter spp., Burkholderia cepacia, Stenotrophomonas maltophilia. Infections caused by GNR may present with diverse clinical picture: bacteremia, pneumonia and other local site infections. Clinical course may be fulminant, with septic shock. Prognosis is frequently worse. Resistance to multiple antibiotic classes, including carbapenems, is growing and it compromises prophylaxis and treatment options. Previous colonization with resistant bacteria and previous exposure to antibiotics are the most important risk factors for infection with resistant bacteria. Treatment of carbapenem-resistant GNR is challenging; in some cases, the only treatment options include old antibiotics (polymyxins and fosfomycin), tigecycline, and aminoglycosides. All these options have efficacy, resistance, and toxicity issues. Continuous monitoring of the local epidemiology combined with antimicrobial stewardship is mandatory for optimization therapy with the currently available drugs. Infectious control is crucial to limit the spread of resistance.


Hematopoietic stem cell and solid organ transplant recipients Gram-negative rods Enterobacteriaceae Pseudomonas aeruginosa Non-fermentative rods Acinetobacter, Stenotrophomonas, Burkholderia, antimicrobial resistance Antimicrobial stewardship Infections control 


  1. 1.
    Engelhard D, Marks MI, Good RA. Infections in bone marrow transplant recipients. J Pediatr. 1986;108(3):335–46.PubMedCrossRefGoogle Scholar
  2. 2.
    Walter EA, Bowden RA. Infection in the bone marrow transplant recipient. Infect Dis Clin North Am. 1995;9(4):823–47.PubMedGoogle Scholar
  3. 3.
    Rubin RH, Tolkoff-Rubin NE. Antimicrobial strategies in the care of organ transplant recipients. Antimicrob Agents Chemother. 1993;37(4):619–24.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Paya CV, Hermans PE, Washington 2nd JA, Smith TF, Anhalt JP, Wiesner RH, et al. Incidence, distribution, and outcome of episodes of infection in 100 orthotopic liver transplantations. Mayo Clin Proc. 1989;64(5):555–64.PubMedCrossRefGoogle Scholar
  5. 5.
    Wade JJ, Rolando N, Hayllar K, Philpott-Howard J, Casewell MW, Williams R. Bacterial and fungal infections after liver transplantation: an analysis of 284 patients. Hepatology. 1995;21(5):1328–36.PubMedCrossRefGoogle Scholar
  6. 6.
    Grossi P, De Maria R, Caroli A, Zaina MS, Minoli L. Infections in heart transplant recipients: the experience of the Italian heart transplantation program. Italian Study Group on Infections in Heart Transplantation. J Heart Lung Transplant. 1992;11(5):847–66.PubMedGoogle Scholar
  7. 7.
    Bert F, Larroque B, Paugam-Burtz C, Janny S, Durand F, Dondero F, et al. Microbial epidemiology and outcome of bloodstream infections in liver transplant recipients: an analysis of 259 episodes. Liver Transpl. 2010;16(3):393–401.PubMedGoogle Scholar
  8. 8.
    Perez F, Adachi J, Bonomo RA. Antibiotic-resistant gram-negative bacterial infections in patients with cancer. Clin Infect Dis. 2014;59 Suppl 5:S335–9.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Gao F, Ye Q, Wan Q, Liu S, Zhou J. Distribution and resistance of pathogens in liver transplant recipients with Acinetobacter baumannii infection. Ther Clin Risk Manag. 2015;11:501–5.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Cordonnier C, Herbrecht R, Buzyn A, Leverger G, Leclercq R, Nitenberg G, et al. Risk factors for Gram-negative bacterial infections in febrile neutropenia. Haematologica. 2005;90(8):1102–9.PubMedGoogle Scholar
  11. 11.
    Cohen ML, Murphy MT, Counts GW, Buckner CD, Clift RA, Meyers JD. Prediction by surveillance cultures of bacteremia among neutropenic patients treated in a protective environment. J Infect Dis. 1983;147(5):789–93.PubMedCrossRefGoogle Scholar
  12. 12.
    Wagener MM, Yu VL. Bacteremia in transplant recipients: a prospective study of demographics, etiologic agents, risk factors, and outcomes. Am J Infect Control. 1992;20(5):239–47.PubMedCrossRefGoogle Scholar
  13. 13.
    Singh N, Paterson DL, Chang FY, Gayowski T, Squier C, Wagener MM, et al. Methicillin-resistant Staphylococcus aureus: the other emerging resistant gram-positive coccus among liver transplant recipients. Clin Infect Dis. 2000;30(2):322–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Klastersky J. Science and pragmatism in the treatment and prevention of neutropenic infection. J Antimicrob Chemother. 1998;41(Suppl D):13–24.PubMedCrossRefGoogle Scholar
  15. 15.
    Collin BA, Leather HL, Wingard JR, Ramphal R. Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. Clin Infect Dis. 2001;33(7):947–53.PubMedCrossRefGoogle Scholar
  16. 16.
    Mikulska M, Del Bono V, Raiola AM, Bruno B, Gualandi F, Occhini D, et al. Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: reemergence of Gram-negative rods and increasing antibiotic resistance. Biol Blood Marrow Transplant. 2009;15(1):47–53.PubMedCrossRefGoogle Scholar
  17. 17.
    Mikulska M, Viscoli C, Orasch C, Livermore DM, Averbuch D, Cordonnier C, et al. Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. J Infect. 2014;68(4):321–31.PubMedCrossRefGoogle Scholar
  18. 18.
    Gudiol C, Bodro M, Simonetti A, Tubau F, Gonzalez-Barca E, Cisnal M, et al. Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients. Clin Microbiol Infect. 2013;19(5):474–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Singh N, Wagener MM, Obman A, Cacciarelli TV, de Vera ME, Gayowski T. Bacteremias in liver transplant recipients: shift toward gram-negative bacteria as predominant pathogens. Liver Transpl. 2004;10(7):844–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Lanini S, Costa AN, Puro V, Procaccio F, Grossi PA, Vespasiano F, et al. Incidence of carbapenem-resistant gram negatives in Italian transplant recipients: a nationwide surveillance study. PLoS One. 2015;10(4):e0123706.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Al-Hasan MN, Razonable RR, Eckel-Passow JE, Baddour LM. Incidence rate and outcome of gram-negative bloodstream infection in solid organ transplant recipients. Am J Transplant. 2009;9(4):835–43.PubMedCrossRefGoogle Scholar
  22. 22.
    Mrzljak A, Peric Z, Kovacevic V, Gustin D, Vrhovac R, Andrasevic AT. Rising problem of multidrug-resistant gram-negative bacteria causing bloodstream infections after liver transplantation: how should we handle the issue? Liver Transpl. 2010;16(10):1217–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Ortega M, Rovira M, Almela M, Marco F, de la Bellacasa JP, Martinez JA, et al. Bacterial and fungal bloodstream isolates from 796 hematopoietic stem cell transplant recipients between 1991 and 2000. Ann Hematol. 2005;84(1):40–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Velasco E, Byington R, Martins CS, Schirmer M, Dias LC, Goncalves VM. Bloodstream infection surveillance in a cancer centre: a prospective look at clinical microbiology aspects. Clin Microbiol Infect. 2004;10(6):542–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Candel FJ, Grima E, Matesanz M, Cervera C, Soto G, Almela M, et al. Bacteremia and septic shock after solid-organ transplantation. Transplant Proc. 2005;37(9):4097–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Bodro M, Sabe N, Tubau F, Llado L, Baliellas C, Roca J, et al. Risk factors and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in solid-organ transplant recipients. Transplantation. 2013;96(9):843–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Poutsiaka DD, Price LL, Ucuzian A, Chan GW, Miller KB, Snydman DR. Blood stream infection after hematopoietic stem cell transplantation is associated with increased mortality. Bone Marrow Transplant. 2007;40(1):63–70.PubMedCrossRefGoogle Scholar
  28. 28.
    Mikulska M, Del Bono V, Bruzzi P, Raiola AM, Gualandi F, Van Lint MT, et al. Mortality after bloodstream infections in allogeneic haematopoietic stem cell transplant (HSCT) recipients. Infection. 2012;40(3):271–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Linares L, Garcia-Goez JF, Cervera C, Almela M, Sanclemente G, Cofan F, et al. Early bacteremia after solid organ transplantation. Transplant Proc. 2009;41(6):2262–4.PubMedCrossRefGoogle Scholar
  30. 30.
    Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268–281.Google Scholar
  31. 31.
    Livermore DM. Mechanisms of resistance to cephalosporin antibiotics. Drugs. 1987;34 Suppl 2:64–88.PubMedCrossRefGoogle Scholar
  32. 32.
    Livermore DM. Mechanisms of resistance to beta-lactam antibiotics. Scand J Infect Dis Suppl. 1991;78:7–16.PubMedGoogle Scholar
  33. 33.
    Livermore DM. Evolution of beta-lactamase inhibitors. Intensive Care Med. 1994;20 Suppl 3:S10–3.PubMedCrossRefGoogle Scholar
  34. 34.
    Livermore DM, Yuan M. Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe. J Antimicrob Chemother. 1996;38(3):409–24.PubMedCrossRefGoogle Scholar
  35. 35.
    Paterson DL. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clin Microbiol Infect. 2000;6(9):460–3.PubMedCrossRefGoogle Scholar
  36. 36.
    Paterson DL. Extended-spectrum beta-lactamases: the European experience. Curr Opin Infect Dis. 2001;14(6):697–701.PubMedCrossRefGoogle Scholar
  37. 37.
    Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18(4):657–86.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis. 2004;39(1):31–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Men TY, Wang JN, Li H, Gu Y, Xing TH, Peng ZH, et al. Prevalence of multidrug-resistant gram-negative bacilli producing extended-spectrum beta-lactamases (ESBLs) and ESBL genes in solid organ transplant recipients. Transpl Infect Dis. 2013;15(1):14–21.PubMedCrossRefGoogle Scholar
  40. 40.
    El Salabi A, Walsh TR, Chouchani C. Extended spectrum beta-lactamases, carbapenemases and mobile genetic elements responsible for antibiotics resistance in Gram-negative bacteria. Crit Rev Microbiol. 2013;39(2):113–22.PubMedCrossRefGoogle Scholar
  41. 41.
    Gudiol C, Calatayud L, Garcia-Vidal C, Lora-Tamayo J, Cisnal M, Duarte R, et al. Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother. 2010;65(2):333–41.PubMedCrossRefGoogle Scholar
  42. 42.
    Gudiol C, Tubau F, Calatayud L, Garcia-Vidal C, Cisnal M, Sanchez-Ortega I, et al. Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. J Antimicrob Chemother. 2011;66(3):657–63.PubMedCrossRefGoogle Scholar
  43. 43.
    Girmenia C, Rossolini GM, Piciocchi A, Bertaina A, Pisapia G, Pastore D, et al. Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy. Bone Marrow Transplant. 2015;50(2):282–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Bossaer JB, Hall PD, Garrett-Mayer E. Incidence of vancomycin-resistant enterococci (VRE) infection in high-risk febrile neutropenic patients colonized with VRE. Support Care Cancer. 2010;19(2):231–7.PubMedCrossRefGoogle Scholar
  45. 45.
    Cohen J, Donnelly JP, Worsley AM, Catovsky D, Goldman JM, Galton DA. Septicaemia caused by viridans streptococci in neutropenic patients with leukaemia. Lancet. 1983;2(8365–66):1452–4.PubMedCrossRefGoogle Scholar
  46. 46.
    Dubberke ER, Hollands JM, Georgantopoulos P, Augustin K, DiPersio JF, Mundy LM, et al. Vancomycin-resistant enterococcal bloodstream infections on a hematopoietic stem cell transplant unit: are the sick getting sicker? Bone Marrow Transplant. 2006;38(12):813–9.PubMedCrossRefGoogle Scholar
  47. 47.
    Kamboj M, Chung D, Seo SK, Pamer EG, Sepkowitz KA, Jakubowski AA, et al. The changing epidemiology of vancomycin-resistant Enterococcus (VRE) bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Biol Blood Marrow Transplant. 2010;16(11):1576–81.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Martinez JA, Aguilar J, Almela M, Marco F, Soriano A, Lopez F, et al. Prior use of carbapenems may be a significant risk factor for extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella spp. in patients with bacteraemia. J Antimicrob Chemother. 2006;58(5):1082–5.PubMedCrossRefGoogle Scholar
  49. 49.
    Narimatsu H, Kami M, Miyakoshi S, Yuji K, Matusmura T, Uchida N, et al. Value of pretransplant screening for colonization of Pseudomonas aeruginosa in reduced-intensity umbilical cord blood transplantation for adult patients. Ann Hematol. 2007;86(6):449–51.PubMedCrossRefGoogle Scholar
  50. 50.
    Ansari SR, Hanna H, Hachem R, Jiang Y, Rolston K, Raad I. Risk factors for infections with multidrug-resistant Stenotrophomonas maltophilia in patients with cancer. Cancer. 2007;109(12):2615–22.PubMedCrossRefGoogle Scholar
  51. 51.
    Tancrede CH, Andremont AO. Bacterial translocation and gram-negative bacteremia in patients with hematological malignancies. J Infect Dis. 1985;152(1):99–103.PubMedCrossRefGoogle Scholar
  52. 52.
    Tsiatis AC, Manes B, Calder C, Billheimer D, Wilkerson KS, Frangoul H. Incidence and clinical complications of vancomycin-resistant enterococcus in pediatric stem cell transplant patients. Bone Marrow Transplant. 2004;33(9):937–41.PubMedCrossRefGoogle Scholar
  53. 53.
    Weinstock DM, Conlon M, Iovino C, Aubrey T, Gudiol C, Riedel E, et al. Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant. 2007;13(5):615–21.PubMedCrossRefGoogle Scholar
  54. 54.
    Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Preface Bone Marrow Transplant. 2009;44(8):453–5.PubMedCrossRefGoogle Scholar
  55. 55.
    Zirakzadeh A, Gastineau DA, Mandrekar JN, Burke JP, Johnston PB, Patel R. Vancomycin-resistant enterococcal colonization appears associated with increased mortality among allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2008;41(4):385–92.PubMedCrossRefGoogle Scholar
  56. 56.
    Winters HA, Parbhoo RK, Schafer JJ, Goff DA. Extended-spectrum beta-lactamase-producing bacterial infections in adult solid organ transplant recipients. Ann Pharmacother. 2011;45(3):309–16.PubMedCrossRefGoogle Scholar
  57. 57.
    Hyle EP, Bilker WB, Gasink LB, Lautenbach E. Impact of different methods for describing the extent of prior antibiotic exposure on the association between antibiotic use and antibiotic-resistant infection. Infect Control Hosp Epidemiol. 2007;28(6):647–54.PubMedCrossRefGoogle Scholar
  58. 58.
    Kim SH, Kwon JC, Choi SM, Lee DG, Park SH, Choi JH, et al. Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum beta-lactamase production and its impact on outcome. Ann Hematol. 2013;92(4):533–41.PubMedCrossRefGoogle Scholar
  59. 59.
    Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis. 2001;32(8):1162–71.PubMedCrossRefGoogle Scholar
  60. 60.
    Ortega M, Marco F, Soriano A, Almela M, Martinez JA, Munoz A, et al. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. J Antimicrob Chemother. 2009;63(3):568–74.PubMedCrossRefGoogle Scholar
  61. 61.
    Tumbarello M, Spanu T, Sanguinetti M, Citton R, Montuori E, Leone F, et al. Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother. 2006;50(2):498–504.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Johnson LE, D'Agata EM, Paterson DL, Clarke L, Qureshi ZA, Potoski BA, et al. Pseudomonas aeruginosa bacteremia over a 10-year period: multidrug resistance and outcomes in transplant recipients. Transpl Infect Dis. 2009;11(3):227–34.PubMedCrossRefGoogle Scholar
  63. 63.
    Ram R, Farbman L, Leibovici L, Raanani P, Yeshurun M, Vidal L, et al. Characteristics of initial compared with subsequent bacterial infections among hospitalised haemato-oncological patients. Int J Antimicrob Agents. 2012;40(2):123–6.PubMedCrossRefGoogle Scholar
  64. 64.
    Linares L, Cervera C, Cofan F, Ricart MJ, Esforzado N, Torregrosa V, et al. Epidemiology and outcomes of multiple antibiotic-resistant bacterial infection in renal transplantation. Transplant Proc. 2007;39(7):2222–4.PubMedCrossRefGoogle Scholar
  65. 65.
    Sopirala MM, Pope-Harman A, Nunley DR, Moffatt-Bruce S, Ross P, Martin SI. Multidrug-resistant Acinetobacter baumannii pneumonia in lung transplant recipients. J Heart Lung Transplant. 2008;27(7):804–7.PubMedCrossRefGoogle Scholar
  66. 66.
    Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med. 2002;136(11):834–44.PubMedCrossRefGoogle Scholar
  67. 67.
    Bow EJ. Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients. Curr Opin Infect Dis. 2011;24(6):545–53.PubMedCrossRefGoogle Scholar
  68. 68.
    Castagnola E, Haupt R, Micozzi A, Caviglia I, Testi AM, Giona F, et al. Differences in the proportions of fluoroquinolone-resistant Gram-negative bacteria isolated from bacteraemic children with cancer in two Italian centres. Clin Microbiol Infect. 2005;11(6):505–7.PubMedCrossRefGoogle Scholar
  69. 69.
    Freire AT, Melnyk V, Kim MJ, Datsenko O, Dzyublik O, Glumcher F, et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis. 2010;68(2):140–51.PubMedCrossRefGoogle Scholar
  70. 70.
    Lopez-Dupla M, Martinez JA, Vidal F, Almela M, Soriano A, Marco F, et al. Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates. Am J Infect Control. 2009;37(9):753–8.PubMedCrossRefGoogle Scholar
  71. 71.
    Trecarichi EM, Pagano L, Candoni A, Pastore D, Cattaneo C, Fanci R, et al. Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey. Clin Microbiol Infect. 2015;21(4):337–43.Google Scholar
  72. 72.
    Trecarichi EM, Tumbarello M, Caira M, Candoni A, Cattaneo C, Pastore D, et al. Multidrug resistant Pseudomonas aeruginosa bloodstream infection in adult patients with hematologic malignancies. Haematologica. 2011;96(1):e1–3. author reply e4.PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Oliveira AL, de Souza M, Carvalho-Dias VM, Ruiz MA, Silla L, Tanaka PY, et al. Epidemiology of bacteremia and factors associated with multi-drug-resistant gram-negative bacteremia in hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2007;39(12):775–81.PubMedCrossRefGoogle Scholar
  74. 74.
    Garnica M, Maiolino A, Nucci M. Factors associated with bacteremia due to multidrug-resistant gram-negative bacilli in hematopoietic stem cell transplant recipients. Braz J Med Biol Res. 2009;42(3):289–93.PubMedCrossRefGoogle Scholar
  75. 75.
    Henning KJ, Delencastre H, Eagan J, Boone N, Brown A, Chung M, et al. Vancomycin-resistant Enterococcus faecium on a pediatric oncology ward: duration of stool shedding and incidence of clinical infection. Pediatr Infect Dis J. 1996;15(10):848–54.PubMedCrossRefGoogle Scholar
  76. 76.
    Bodro M, Sabe N, Tubau F, Llado L, Baliellas C, Gonzalez-Costello J, et al. Extensively drug-resistant Pseudomonas aeruginosa bacteremia in solid organ transplant recipients. Transplantation. 2015;99(3):616–22.PubMedCrossRefGoogle Scholar
  77. 77.
    Linares L, Cervera C, Cofan F, Lizaso D, Marco F, Ricart MJ, et al. Risk factors for infection with extended-spectrum and AmpC beta-lactamase-producing gram-negative rods in renal transplantation. Am J Transplant. 2008;8(5):1000–5.PubMedCrossRefGoogle Scholar
  78. 78.
    Brizendine KD, Richter SS, Cober ED, van Duin D. Carbapenem-resistant Klebsiella pneumoniae urinary tract infection following solid organ transplantation. Antimicrob Agents Chemother. 2015;59(1):553–7.PubMedCrossRefGoogle Scholar
  79. 79.
    Trecarichi EM, Tumbarello M, Spanu T, Caira M, Fianchi L, Chiusolo P, et al. Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J Infect. 2009;58(4):299–307.PubMedCrossRefGoogle Scholar
  80. 80.
    Ariffin H, Navaratnam P, Mohamed M, Arasu A, Abdullah WA, Lee CL, et al. Ceftazidime-resistant Klebsiella pneumoniae bloodstream infection in children with febrile neutropenia. Int J Infect Dis. 2000;4(1):21–5.PubMedCrossRefGoogle Scholar
  81. 81.
    Kang CI, Chung DR, Ko KS, Peck KR, Song JH. Risk factors for infection and treatment outcome of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy. Ann Hematol. 2012;91(1):115–21.PubMedCrossRefGoogle Scholar
  82. 82.
    Marchaim D, Navon-Venezia S, Schwaber MJ, Carmeli Y. Isolation of imipenem-resistant Enterobacter species: emergence of KPC-2 carbapenemase, molecular characterization, epidemiology, and outcomes. Antimicrob Agents Chemother. 2008;52(4):1413–8.PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Moreno A, Cervera C, Gavalda J, Rovira M, de la Camara R, Jarque I, et al. Bloodstream infections among transplant recipients: results of a nationwide surveillance in Spain. Am J Transplant. 2007;7(11):2579–86.PubMedCrossRefGoogle Scholar
  84. 84.
    Lubbert C, Becker-Rux D, Rodloff AC, Laudi S, Busch T, Bartels M, et al. Colonization of liver transplant recipients with KPC-producing Klebsiella pneumoniae is associated with high infection rates and excess mortality: a case-control analysis. Infection. 2014;42(2):309–16.PubMedCrossRefGoogle Scholar
  85. 85.
    Nunley DR, Bauldoff GS, Mangino JE, Pope-Harman AL. Mortality associated with Acinetobacter baumannii infections experienced by lung transplant recipients. Lung. 2010;188(5):381–5.PubMedCrossRefGoogle Scholar
  86. 86.
    Elting LS, Rubenstein EB, Rolston KV, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis. 1997;25(2):247–59.PubMedCrossRefGoogle Scholar
  87. 87.
    Martinez JA, Cobos-Trigueros N, Soriano A, Almela M, Ortega M, Marco F, et al. Influence of empiric therapy with a beta-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to gram-negative microorganisms. Antimicrob Agents Chemother. 2010;54(9):3590–6.PubMedPubMedCentralCrossRefGoogle Scholar
  88. 88.
    Lupei MI, Mann HJ, Beilman GJ, Oancea C, Chipman JG. Inadequate antibiotic therapy in solid organ transplant recipients is associated with a higher mortality rate. Surg Infect. 2010;11(1):33–9.CrossRefGoogle Scholar
  89. 89.
    de Gouvea EF, Martins IS, Halpern M, Ferreira AL, Basto ST, Goncalves RT, et al. The influence of carbapenem resistance on mortality in solid organ transplant recipients with Acinetobacter baumannii infection. BMC Infect Dis. 2012;12:351.PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Deusch E, End A, Grimm M, Graninger W, Klepetko W, Wolner E. Early bacterial infections in lung transplant recipients. Chest. 1993;104(5):1412–6.PubMedCrossRefGoogle Scholar
  91. 91.
    Takai K, Aoki A, Suga A, Tollemar J, Wilczek HE, Naito K, et al. Urinary tract infections following renal transplantation. Transplant Proc. 1998;30(7):3140–1.PubMedCrossRefGoogle Scholar
  92. 92.
    Bonatti H, Pruett TL, Brandacher G, Hagspiel KD, Housseini AM, Sifri CD, et al. Pneumonia in solid organ recipients: spectrum of pathogens in 217 episodes. Transplant Proc. 2009;41(1):371–4.PubMedCrossRefGoogle Scholar
  93. 93.
    Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis. 2009;9(4):228–36.PubMedCrossRefGoogle Scholar
  94. 94.
    Nordmann P, Dortet L, Poirel L. Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends Mol Med. 2012;18(5):263–72.PubMedCrossRefGoogle Scholar
  95. 95.
    Perez F, Van Duin D. Carbapenem-resistant Enterobacteriaceae: a menace to our most vulnerable patients. Cleve Clin J Med. 2013;80(4):225–33.PubMedPubMedCentralCrossRefGoogle Scholar
  96. 96.
    Snitkin ES, Zelazny AM, Thomas PJ, Stock F, Henderson DK, Palmore TN, et al. Tracking a hospital outbreak of carbapenem-resistant Klebsiella pneumoniae with whole-genome sequencing. Sci Transl Med. 2012;4(148):148ra116.PubMedPubMedCentralCrossRefGoogle Scholar
  97. 97.
    Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013;13(9):785–96.PubMedPubMedCentralCrossRefGoogle Scholar
  98. 98.
    Kitchel B, Rasheed JK, Patel JB, Srinivasan A, Navon-Venezia S, Carmeli Y, et al. Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258. Antimicrob Agents Chemother. 2009;53(8):3365–70.PubMedPubMedCentralCrossRefGoogle Scholar
  99. 99.
    Schwaber MJ, Lev B, Israeli A, Solter E, Smollan G, Rubinovitch B, et al. Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin Infect Dis. 2011;52(7):848–55.PubMedCrossRefGoogle Scholar
  100. 100.
    Satlin MJ, Jenkins SG, Walsh TJ. The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies. Clin Infect Dis. 2014;58(9):1274–83.PubMedPubMedCentralCrossRefGoogle Scholar
  101. 101.
    Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis. 2010;10(9):597–602.PubMedPubMedCentralCrossRefGoogle Scholar
  102. 102.
    Livermore DM, Warner M, Mushtaq S, Doumith M, Zhang J, Woodford N. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents. 2011;37(5):415–9.PubMedCrossRefGoogle Scholar
  103. 103.
    Wroblewska MM, Marchel H, Luczak M. Multidrug resistance in bacterial isolates from blood cultures of haematology patients. Int J Antimicrob Agents. 2002;19(3):237–40.PubMedCrossRefGoogle Scholar
  104. 104.
    Pagano L, Caira M, Trecarichi EM, Spanu T, Di Blasi R, Sica S, et al. Carbapenemase-producing Klebsiella pneumoniae and hematologic malignancies. Emerg Infect Dis. 2014;20(7):1235–6.PubMedPubMedCentralCrossRefGoogle Scholar
  105. 105.
    Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol. 2008;29(12):1099–106.PubMedCrossRefGoogle Scholar
  106. 106.
    van Duin D, van Delden C. Multidrug-resistant gram-negative bacteria infections in solid organ transplantation. Am J Transplant. 2013;13 Suppl 4:31–41.PubMedCrossRefGoogle Scholar
  107. 107.
    Bellier C, Bert F, Durand F, Retout S, Belghiti J, Mentre F, et al. Risk factors for Enterobacteriaceae bacteremia after liver transplantation. Transpl Int. 2008;21(8):755–63.PubMedCrossRefGoogle Scholar
  108. 108.
    Pinheiro HS, Mituiassu AM, Carminatti M, Braga AM, Bastos MG. Urinary tract infection caused by extended-spectrum beta-lactamase-producing bacteria in kidney transplant patients. Transplant Proc. 2010;42(2):486–7.PubMedCrossRefGoogle Scholar
  109. 109.
    Green M, Barbadora K. Recovery of ceftazidime-resistant Klebsiella pneumoniae from pediatric liver and intestinal transplant recipients. Pediatr Transplant. 1998;2(3):224–30.PubMedGoogle Scholar
  110. 110.
    Valera B, Gentil MA, Cabello V, Fijo J, Cordero E, Cisneros JM. Epidemiology of urinary infections in renal transplant recipients. Transplant Proc. 2006;38(8):2414–5.PubMedCrossRefGoogle Scholar
  111. 111.
    Rebuck JA, Olsen KM, Fey PD, Langnas AN, Rupp ME. Characterization of an outbreak due to extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a pediatric intensive care unit transplant population. Clin Infect Dis. 2000;31(6):1368–72.PubMedCrossRefGoogle Scholar
  112. 112.
    Laupland KB, Gregson DB, Church DL, Ross T, Pitout JD. Incidence, risk factors and outcomes of Escherichia coli bloodstream infections in a large Canadian region. Clin Microbiol Infect. 2008;14(11):1041–7.PubMedCrossRefGoogle Scholar
  113. 113.
    Nguyen M, Eschenauer GA, Bryan M, O’Neil K, Furuya EY, Della-Latta P, et al. Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes. Diagn Microbiol Infect Dis. 2010;67(2):180–4.PubMedCrossRefGoogle Scholar
  114. 114.
    Cicora F, Mos F, Paz M, Allende NG, Roberti J. Infections with blaKPC-2-producing Klebsiella pneumoniae in renal transplant patients: a retrospective study. Transplant Proc. 2013;45(9):3389–93.PubMedCrossRefGoogle Scholar
  115. 115.
    Bergamasco MD, Barroso Barbosa M, de Oliveira Garcia D, Cipullo R, Moreira JC, Baia C, et al. Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae in solid organ transplantation. Transpl Infect Dis. 2012;14(2):198–205.PubMedCrossRefGoogle Scholar
  116. 116.
    Clancy CJ, Chen L, Shields RK, Zhao Y, Cheng S, Chavda KD, et al. Epidemiology and molecular characterization of bacteremia due to carbapenem-resistant Klebsiella pneumoniae in transplant recipients. Am J Transplant. 2013;13(10):2619–33.PubMedPubMedCentralCrossRefGoogle Scholar
  117. 117.
    Borer A, Saidel-Odes L, Eskira S, Nativ R, Riesenberg K, Livshiz-Riven I, et al. Risk factors for developing clinical infection with carbapenem-resistant Klebsiella pneumoniae in hospital patients initially only colonized with carbapenem-resistant K pneumoniae. Am J Infect Control. 2012;40(5):421–5.PubMedCrossRefGoogle Scholar
  118. 118.
    Giannella M, Trecarichi EM, De Rosa FG, Del Bono V, Bassetti M, Lewis RE, et al. Risk factors for carbapenem-resistant Klebsiella pneumoniae bloodstream infection among rectal carriers: a prospective observational multicentre study. Clin Microbiol Infect. 2014;20(12):1357–62.PubMedCrossRefGoogle Scholar
  119. 119.
    Schechner V, Kotlovsky T, Kazma M, Mishali H, Schwartz D, Navon-Venezia S, et al. Asymptomatic rectal carriage of blaKPC producing carbapenem-resistant Enterobacteriaceae: who is prone to become clinically infected? Clin Microbiol Infect. 2013;19(5):451–6.PubMedCrossRefGoogle Scholar
  120. 120.
    Giannella M, Bartoletti M, Morelli MC, Tedeschi S, Cristini F, Tumietto F, et al. Risk factors for infection with carbapenem-resistant Klebsiella pneumoniae after liver transplantation: the importance of pre- and posttransplant colonization. Am J Transplant. 2015;15(6):1708–15.PubMedCrossRefGoogle Scholar
  121. 121.
    Schwaber MJ, Carmeli Y. Carbapenem-resistant Enterobacteriaceae: a potential threat. JAMA. 2008;300(24):2911–3.PubMedCrossRefGoogle Scholar
  122. 122.
    Daikos GL, Petrikkos P, Psichogiou M, Kosmidis C, Vryonis E, Skoutelis A, et al. Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob Agents Chemother. 2009;53(5):1868–73.PubMedPubMedCentralCrossRefGoogle Scholar
  123. 123.
    Borer A, Saidel-Odes L, Riesenberg K, Eskira S, Peled N, Nativ R, et al. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia. Infect Control Hosp Epidemiol. 2009;30(10):972–6.PubMedCrossRefGoogle Scholar
  124. 124.
    Satlin MJ, Calfee DP, Chen L, Fauntleroy KA, Wilson SJ, Jenkins SG, et al. Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignancies. Leukemia Lymphoma. 2013;54(4):799–806.PubMedCrossRefGoogle Scholar
  125. 125.
    Kalpoe JS, Sonnenberg E, Factor SH, del Rio Martin J, Schiano T, Patel G, et al. Mortality associated with carbapenem-resistant Klebsiella pneumoniae infections in liver transplant recipients. Liver Transpl. 2012;18(4):468–74.PubMedCrossRefGoogle Scholar
  126. 126.
    Simkins J, Muggia V, Cohen HW, Minamoto GY. Carbapenem-resistant Klebsiella pneumoniae infections in kidney transplant recipients: a case-control study. Transpl Infect Dis. 2014;16(5):775–82.PubMedCrossRefGoogle Scholar
  127. 127.
    Capone A, Giannella M, Fortini D, Giordano A, Meledandri M, Ballardini M, et al. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect. 2013;19(1):E23–30.PubMedCrossRefGoogle Scholar
  128. 128.
    Paterson DL, Ko WC, Von Gottberg A, Casellas JM, Mulazimoglu L, Klugman KP, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol. 2001;39(6):2206–12.PubMedPubMedCentralCrossRefGoogle Scholar
  129. 129.
    Chow JW, Fine MJ, Shlaes DM, Quinn JP, Hooper DC, Johnson MP, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med. 1991;115(8):585–90.PubMedCrossRefGoogle Scholar
  130. 130.
    Kaye KS, Cosgrove S, Harris A, Eliopoulos GM, Carmeli Y. Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp. Antimicrob Agents Chemother. 2001;45(9):2628–30.PubMedPubMedCentralCrossRefGoogle Scholar
  131. 131.
    Choi SH, Lee JE, Park SJ, Lee SO, Jeong JY, Kim MN, et al. Emergence of antibiotic resistance during therapy for infections caused by Enterobacteriaceae producing AmpC beta-lactamase: implications for antibiotic use. Antimicrob Agents Chemother. 2008;52(3):995–1000.PubMedCrossRefGoogle Scholar
  132. 132.
    Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev. 2009;22(1):161–82. Table of Contents.PubMedPubMedCentralCrossRefGoogle Scholar
  133. 133.
    Lopez-Cerero L, Picon E, Morillo C, Hernandez JR, Docobo F, Pachon J, et al. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates. Clin Microbiol Infect. 2010;16(2):132–6.PubMedCrossRefGoogle Scholar
  134. 134.
    Paterson DL, Mulazimoglu L, Casellas JM, Ko WC, Goossens H, Von Gottberg A, et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis. 2000;30(3):473–8.PubMedCrossRefGoogle Scholar
  135. 135.
    Falagas ME, Karageorgopoulos DE. Extended-spectrum beta-lactamase-producing organisms. J Hosp Infect. 2009;73(4):345–54.PubMedCrossRefGoogle Scholar
  136. 136.
    Kim SB, Min YH, Cheong JW, Kim JS, Kim SJ, Ku NS, et al. Incidence and risk factors for carbapenem- and multidrug-resistant Acinetobacter baumannii bacteremia in hematopoietic stem cell transplantation recipients. Scand J Infect Dis. 2014;46(2):81–8.PubMedCrossRefGoogle Scholar
  137. 137.
    Araoka H, Fujii T, Izutsu K, Kimura M, Nishida A, Ishiwata K, et al. Rapidly progressive fatal hemorrhagic pneumonia caused by Stenotrophomonas maltophilia in hematologic malignancy. Transpl Infect Dis. 2012;14(4):355–63.PubMedCrossRefGoogle Scholar
  138. 138.
    Tada K, Kurosawa S, Hiramoto N, Okinaka K, Ueno N, Asakura Y, et al. Stenotrophomonas maltophilia infection in hematopoietic SCT recipients: high mortality due to pulmonary hemorrhage. Bone Marrow Transplant. 2013;48(1):74–9.PubMedCrossRefGoogle Scholar
  139. 139.
    Martino R, Gomez L, Pericas R, Salazar R, Sola C, Sierra J, et al. Bacteraemia caused by non-glucose-fermenting gram-negative bacilli and Aeromonas species in patients with haematological malignancies and solid tumours. Eur J Clin Microbiol Infect Dis. 2000;19(4):320–3.PubMedCrossRefGoogle Scholar
  140. 140.
    Cattaneo C, Quaresmini G, Casari S, Capucci MA, Micheletti M, Borlenghi E, et al. Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution. J Antimicrob Chemother. 2008;61(3):721–8.PubMedCrossRefGoogle Scholar
  141. 141.
    Saavedra S, Sanz GF, Jarque I, Moscardo F, Jimenez C, Lorenzo I, et al. Early infections in adult patients undergoing unrelated donor cord blood transplantation. Bone Marrow Transplant. 2002;30(12):937–43.PubMedCrossRefGoogle Scholar
  142. 142.
    Mullen CA, Nair J, Sandesh S, Chan KW. Fever and neutropenia in pediatric hematopoietic stem cell transplant patients. Bone Marrow Transplant. 2000;25(1):59–65.PubMedCrossRefGoogle Scholar
  143. 143.
    Narimatsu H, Matsumura T, Kami M, Miyakoshi S, Kusumi E, Takagi S, et al. Bloodstream infection after umbilical cord blood transplantation using reduced-intensity stem cell transplantation for adult patients. Biol Blood Marrow Transplant. 2005;11(6):429–36.PubMedCrossRefGoogle Scholar
  144. 144.
    Yazaki M, Atsuta Y, Kato K, Kato S, Taniguchi S, Takahashi S, et al. Incidence and risk factors of early bacterial infections after unrelated cord blood transplantation. Biol Blood Marrow Transplant. 2009;15(4):439–46.PubMedCrossRefGoogle Scholar
  145. 145.
    Dettenkofer M, Wenzler-Rottele S, Babikir R, Bertz H, Ebner W, Meyer E, et al. Surveillance of nosocomial sepsis and pneumonia in patients with a bone marrow or peripheral blood stem cell transplant: a multicenter project. Clin Infect Dis. 2005;40(7):926–31.PubMedCrossRefGoogle Scholar
  146. 146.
    Singh N, Gayowski T, Wagener MM, Marino IR. Predictors and outcome of early- versus late-onset major bacterial infections in liver transplant recipients receiving tacrolimus (FK506) as primary immunosuppression. Eur J Clin Microbiol Infect Dis. 1997;16(11):821–6.PubMedCrossRefGoogle Scholar
  147. 147.
    Aguilar-Guisado M, Givalda J, Ussetti P, Ramos A, Morales P, Blanes M, et al. Pneumonia after lung transplantation in the RESITRA Cohort: a multicenter prospective study. Am J Transplant. 2007;7(8):1989–96.PubMedCrossRefGoogle Scholar
  148. 148.
    Campos S, Caramori M, Teixeira R, Afonso Jr J, Carraro R, Strabelli T, et al. Bacterial and fungal pneumonias after lung transplantation. Transplant Proc. 2008;40(3):822–4.PubMedCrossRefGoogle Scholar
  149. 149.
    Mahenthiralingam E, Vandamme P, Campbell ME, Henry DA, Gravelle AM, Wong LT, et al. Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace Burkholderia multivorans. Clin Infect Dis. 2001;33(9):1469–75.PubMedCrossRefGoogle Scholar
  150. 150.
    Agodi A, Barchitta M, Giannino V, Collura A, Pensabene T, Garlaschi ML, et al. Burkholderia cepacia complex in cystic fibrosis and non-cystic fibrosis patients: identification of a cluster of epidemic lineages. J Hosp Infect. 2002;50(3):188–95.PubMedCrossRefGoogle Scholar
  151. 151.
    Agodi A, Mahenthiralingam E, Barchitta M, Giannino V, Sciacca A, Stefani S. Burkholderia cepacia complex infection in Italian patients with cystic fibrosis: prevalence, epidemiology, and genomovar status. J Clin Microbiol. 2001;39(8):2891–6.PubMedPubMedCentralCrossRefGoogle Scholar
  152. 152.
    Teo WY, Chan MY, Lam CM, Chong CY. Skin manifestation of Stenotrophomonas maltophilia infection—a case report and review article. Ann Acad Med Singapore. 2006;35(12):897–900.PubMedGoogle Scholar
  153. 153.
    Botha P, Archer L, Anderson RL, Lordan J, Dark JH, Corris PA, et al. Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome. Transplantation. 2008;85(5):771–4.PubMedCrossRefGoogle Scholar
  154. 154.
    Ramirez J, Dartois N, Gandjini H, Yan JL, Korth-Bradley J, McGovern PC. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother. 2013;57(4):1756–62.PubMedPubMedCentralCrossRefGoogle Scholar
  155. 155.
    Hakki M, Limaye AP, Kim HW, Kirby KA, Corey L, Boeckh M. Invasive Pseudomonas aeruginosa infections: high rate of recurrence and mortality after hematopoietic cell transplantation. Bone Marrow Transplant. 2007;39(11):687–93.PubMedCrossRefGoogle Scholar
  156. 156.
    Yeshurun M, Gafter-Gvili A, Thaler M, Keller N, Nagler A, Shimoni A. Clinical characteristics of Stenotrophomonas maltophilia infection in hematopoietic stem cell transplantation recipients: a single center experience. Infection. 2010;38(3):211–5.PubMedCrossRefGoogle Scholar
  157. 157.
    Shi SH, Kong HS, Xu J, Zhang WJ, Jia CK, Wang WL, et al. Multidrug resistant gram-negative bacilli as predominant bacteremic pathogens in liver transplant recipients. Transpl Infect Dis. 2009;11(5):405–12.PubMedCrossRefGoogle Scholar
  158. 158.
    Shiratori S, Wakasa K, Okada K, Sugita J, Akizawa K, Shigematsu A, et al. Stenotrophomonas maltophilia infection during allogeneic hematopoietic stem cell transplantation: a single-center experience. Clin Transpl. 2014;28(6):656–61.CrossRefGoogle Scholar
  159. 159.
    Snell GI, de Hoyos A, Krajden M, Winton T, Maurer JR. Pseudomonas cepacia in lung transplant recipients with cystic fibrosis. Chest. 1993;103(2):466–71.PubMedCrossRefGoogle Scholar
  160. 160.
    Isles A, Maclusky I, Corey M, Gold R, Prober C, Fleming P, et al. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr. 1984;104(2):206–10.PubMedCrossRefGoogle Scholar
  161. 161.
    LiPuma JJ, Dasen SE, Nielson DW, Stern RC, Stull TL. Person-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis. Lancet. 1990;336(8723):1094–6.PubMedCrossRefGoogle Scholar
  162. 162.
    Chaparro C, Maurer J, Gutierrez C, Krajden M, Chan C, Winton T, et al. Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation. Am J Respir Crit Care Med. 2001;163(1):43–8.PubMedCrossRefGoogle Scholar
  163. 163.
    Meachery G, De Soyza A, Nicholson A, Parry G, Hasan A, Tocewicz K, et al. Outcomes of lung transplantation for cystic fibrosis in a large UK cohort. Thorax. 2008;63(8):725–31.PubMedCrossRefGoogle Scholar
  164. 164.
    Egan JJ, McNeil K, Bookless B, Gould K, Corris P, Higenbottam T, et al. Post-transplantation survival of cystic fibrosis patients infected with Pseudomonas cepacia. Lancet. 1994;344(8921):552–3.PubMedCrossRefGoogle Scholar
  165. 165.
    Flume PA, Egan TM, Paradowski LJ, Detterbeck FC, Thompson JT, Yankaskas JR. Infectious complications of lung transplantation. Impact of cystic fibrosis. Am J Respir Crit Care Med. 1994;149(6):1601–7.PubMedCrossRefGoogle Scholar
  166. 166.
    De Soyza A, McDowell A, Archer L, Dark JH, Elborn SJ, Mahenthiralingam E, et al. Burkholderia cepacia complex genomovars and pulmonary transplantation outcomes in patients with cystic fibrosis. Lancet. 2001;358(9295):1780–1.PubMedCrossRefGoogle Scholar
  167. 167.
    De Soyza A, Archer L, McDowell A, Moore J, Dark JH, Elborn S, et al. Lung transplantation for cystic fibrosis; the effect of B cepacia genomovars on post transplant outcomes. J Heart Lung Transplant. 2001;20(2):158.PubMedCrossRefGoogle Scholar
  168. 168.
    Alexander BD, Petzold EW, Reller LB, Palmer SM, Davis RD, Woods CW, et al. Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia cepacia complex. Am J Transplant. 2008;8(5):1025–30.PubMedCrossRefGoogle Scholar
  169. 169.
    De Soyza A, Meachery G, Hester KL, Nicholson A, Parry G, Tocewicz K, et al. Lung transplantation for patients with cystic fibrosis and Burkholderia cepacia complex infection: a single-center experience. J Heart Lung Transplant. 2010;29(12):1395–404.PubMedCrossRefGoogle Scholar
  170. 170.
    Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis. 2002;34(5):634–40.PubMedCrossRefGoogle Scholar
  171. 171.
    Cornaglia G, Mazzariol A, Lauretti L, Rossolini GM, Fontana R. Hospital outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-1, a novel transferable metallo-beta-lactamase. Clin Infect Dis. 2000;31(5):1119–25.PubMedCrossRefGoogle Scholar
  172. 172.
    Livermore DM. Of Pseudomonas, porins, pumps and carbapenems. J Antimicrob Chemother. 2001;47(3):247–50.PubMedCrossRefGoogle Scholar
  173. 173.
    Trepanier S, Prince A, Huletsky A. Characterization of the penA and penR genes of Burkholderia cepacia 249 which encode the chromosomal class A penicillinase and its LysR-type transcriptional regulator. Antimicrob Agents Chemother. 1997;41(11):2399–405.PubMedPubMedCentralGoogle Scholar
  174. 174.
    Baxter IA, Lambert PA. Isolation and partial purification of a carbapenem-hydrolysing metallo-beta-lactamase from Pseudomonas cepacia. FEMS Microbiol Lett. 1994;122(3):251–6.PubMedGoogle Scholar
  175. 175.
    Joris B, Galleni M, Frere JM, Labia R. Analysis of the penA gene of Pseudomonas cepacia 249. Antimicrob Agents Chemother. 1994;38(2):407–8.PubMedPubMedCentralCrossRefGoogle Scholar
  176. 176.
    Simpson IN, Hunter R, Govan JR, Nelson JW. Do all Pseudomonas cepacia produce carbapenemases? J Antimicrob Chemother. 1993;32(2):339–41.PubMedCrossRefGoogle Scholar
  177. 177.
    Proenca R, Niu WW, Cacalano G, Prince A. The Pseudomonas cepacia 249 chromosomal penicillinase is a member of the AmpC family of chromosomal beta-lactamases. Antimicrob Agents Chemother. 1993;37(4):667–74.PubMedPubMedCentralCrossRefGoogle Scholar
  178. 178.
    Aronoff SC. Outer membrane permeability in Pseudomonas cepacia: diminished porin content in a beta-lactam-resistant mutant and in resistant cystic fibrosis isolates. Antimicrob Agents Chemother. 1988;32(11):1636–9.PubMedPubMedCentralCrossRefGoogle Scholar
  179. 179.
    Prince A, Wood MS, Cacalano GS, Chin NX. Isolation and characterization of a penicillinase from Pseudomonas cepacia 249. Antimicrob Agents Chemother. 1988;32(6):838–43.PubMedPubMedCentralCrossRefGoogle Scholar
  180. 180.
    Hsueh PR, Teng LJ, Chen CY, Chen WH, Yu CJ, Ho SW, et al. Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital. Taiwan Emerg Infect Dis. 2002;8(8):827–32.PubMedCrossRefGoogle Scholar
  181. 181.
    Levin AS. Multiresistant Acinetobacter infections: a role for sulbactam combinations in overcoming an emerging worldwide problem. Clin Microbiol Infect. 2002;8(3):144–53.PubMedCrossRefGoogle Scholar
  182. 182.
    Caselli D, Cesaro S, Ziino O, Zanazzo G, Manicone R, Livadiotti S, et al. Multidrug resistant Pseudomonas aeruginosa infection in children undergoing chemotherapy and hematopoietic stem cell transplantation. Haematologica. 2010;95(9):1612–5.PubMedPubMedCentralCrossRefGoogle Scholar
  183. 183.
    Labarca JA, Leber AL, Kern VL, Territo MC, Brankovic LE, Bruckner DA, et al. Outbreak of Stenotrophomonas maltophilia bacteremia in allogenic bone marrow transplant patients: role of severe neutropenia and mucositis. Clin Infect Dis. 2000;30(1):195–7.PubMedCrossRefGoogle Scholar
  184. 184.
    Klausner JD, Zukerman C, Limaye AP, Corey L. Outbreak of Stenotrophomonas maltophilia bacteremia among patients undergoing bone marrow transplantation: association with faulty replacement of handwashing soap. Infect Control Hosp Epidemiol. 1999;20(11):756–8.PubMedCrossRefGoogle Scholar
  185. 185.
    Paez J, Levin AS, Fu L, Basso M, Fonseca GH, Dulley FL, et al. Clusters of infection due to metallo-beta-lactamase-producing Pseudomonas aeruginosa in stem cell transplant and haematology units. J Hosp Infect. 2011;77(1):76–7.PubMedCrossRefGoogle Scholar
  186. 186.
    Sganga G, Spanu T, Bianco G, Fiori B, Nure E, Pepe G, et al. Bacterial bloodstream infections in liver transplantation: etiologic agents and antimicrobial susceptibility profiles. Transplant Proc. 2012;44(7):1973–6.PubMedCrossRefGoogle Scholar
  187. 187.
    Silveira FP, Marcos A, Kwak EJ, Husain S, Shapiro R, Thai N, et al. Bloodstream infections in organ transplant recipients receiving alemtuzumab: no evidence of occurrence of organisms typically associated with profound T cell depletion. J Infect. 2006;53(4):241–7.PubMedCrossRefGoogle Scholar
  188. 188.
    Reddy P, Zembower TR, Ison MG, Baker TA, Stosor V. Carbapenem-resistant Acinetobacter baumannii infections after organ transplantation. Transpl Infect Dis. 2010;12(1):87–93.PubMedCrossRefGoogle Scholar
  189. 189.
    Shields RK, Clancy CJ, Gillis LM, Kwak EJ, Silveira FP, Massih RC, et al. Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients. PLoS One. 2012;7(12):e52349.PubMedPubMedCentralCrossRefGoogle Scholar
  190. 190.
    Hadjiliadis D, Steele MP, Chaparro C, Singer LG, Waddell TK, Hutcheon MA, et al. Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than Burkholderia cepacia, compared with patients harboring sensitive bacteria. J Heart Lung Transplant. 2007;26(8):834–8.PubMedCrossRefGoogle Scholar
  191. 191.
    Dobbin C, Maley M, Harkness J, Benn R, Malouf M, Glanville A, et al. The impact of pan-resistant bacterial pathogens on survival after lung transplantation in cystic fibrosis: results from a single large referral centre. J Hosp Infect. 2004;56(4):277–82.PubMedCrossRefGoogle Scholar
  192. 192.
    Boussaud V, Guillemain R, Grenet D, Coley N, Souilamas R, Bonnette P, et al. Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with Burkholderia cepacia complex: results from two French centres. Thorax. 2008;63(8):732–7.PubMedCrossRefGoogle Scholar
  193. 193.
    Murray S, Charbeneau J, Marshall BC, LiPuma JJ. Impact of burkholderia infection on lung transplantation in cystic fibrosis. Am J Respir Crit Care Med. 2008;178(4):363–71.PubMedCrossRefGoogle Scholar
  194. 194.
    Saiman L, Siegel JD, LiPuma JJ, Brown RF, Bryson EA, Chambers MJ, et al. Infection prevention and control guideline for cystic fibrosis: 2013 update. Infect Control Hosp Epidemiol. 2014;35 Suppl 1:S1–67.PubMedCrossRefGoogle Scholar
  195. 195.
    Shields RK, Kwak EJ, Potoski BA, Doi Y, Adams-Haduch JM, Silviera FP, et al. High mortality rates among solid organ transplant recipients infected with extensively drug-resistant Acinetobacter baumannii: using in vitro antibiotic combination testing to identify the combination of a carbapenem and colistin as an effective treatment regimen. Diagn Microbiol Infect Dis. 2011;70(2):246–52.PubMedCrossRefGoogle Scholar
  196. 196.
    Freire MP, Van Der Heijden IM, do Prado GV, Cavalcante LS, Boszczowski I, Bonazzi PR, et al. Polymyxin use as a risk factor for colonization or infection with polymyxin-resistant Acinetobacter baumannii after liver transplantation. Transpl Infect Dis. 2014;16(3):369–78.PubMedCrossRefGoogle Scholar
  197. 197.
    Hilf M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA, Muder RR. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med. 1989;87(5):540–6.PubMedCrossRefGoogle Scholar
  198. 198.
    Leibovici L, Paul M, Poznanski O, Drucker M, Samra Z, Konigsberger H, et al. Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Antimicrob Agents Chemother. 1997;41(5):1127–33.PubMedPubMedCentralGoogle Scholar
  199. 199.
    Vidal F, Mensa J, Almela M, Martinez JA, Marco F, Casals C, et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch Intern Med. 1996;156(18):2121–6.PubMedCrossRefGoogle Scholar
  200. 200.
    Vardakas KZ, Tansarli GS, Bliziotis IA, Falagas ME. beta-Lactam plus aminoglycoside or fluoroquinolone combination versus beta-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis. Int J Antimicrob Agents. 2013;41(4):301–10.PubMedCrossRefGoogle Scholar
  201. 201.
    Paterson DL, Playford EG. Should third-generation cephalosporins be the empirical treatment of choice for severe community-acquired pneumonia in adults? Med J Aust. 1998;168(7):344–8.PubMedGoogle Scholar
  202. 202.
    Johnson DE, Thompson B. Efficacy of single-agent therapy with azlocillin, ticarcillin, and amikacin and beta-lactam/amikacin combinations for treatment of Pseudomonas aeruginosa bacteremia in granulocytopenic rats. Am J Med. 1986;80(5C):53–8.PubMedGoogle Scholar
  203. 203.
    Winston DJ, Barnes RC, Ho WG, Young LS, Champlin RE, Gale RP. Moxalactam plus piperacillin versus moxalactam plus amikacin in febrile granulocytopenic patients. Am J Med. 1984;77(3):442–50.PubMedCrossRefGoogle Scholar
  204. 204.
    Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis. 2008;46(7):1069–77.PubMedCrossRefGoogle Scholar
  205. 205.
    Nicodemo AC, Paez JI. Antimicrobial therapy for Stenotrophomonas maltophilia infections. Eur J Clin Microbiol Infect Dis. 2007;26(4):229–37.PubMedCrossRefGoogle Scholar
  206. 206.
    Safdar A, Rolston KV. Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer. Clin Infect Dis. 2007;45(12):1602–9.PubMedCrossRefGoogle Scholar
  207. 207.
    Venditti M, Monaco M, Micozzi A, Tarasi A, Friedrich A, Martino P. In vitro activity of moxifloxacin against Stenotrophomonas maltophilia blood isolates from patients with hematologic malignancies. Clin Microbiol Infect. 2001;7(1):37–9.PubMedCrossRefGoogle Scholar
  208. 208.
    Muder RR, Harris AP, Muller S, Edmond M, Chow JW, Papadakis K, et al. Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes. Clin Infect Dis. 1996;22(3):508–12.PubMedCrossRefGoogle Scholar
  209. 209.
    Cercenado E, Unal S, Eliopoulos CT, Rubin LG, Isenberg HD, Moellering Jr RC, et al. Characterization of vancomycin resistance in Enterococcus durans. J Antimicrob Chemother. 1995;36(5):821–5.PubMedCrossRefGoogle Scholar
  210. 210.
    Cisneros JM, Reyes MJ, Pachon J, Becerril B, Caballero FJ, Garcia-Garmendia JL, et al. Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin Infect Dis. 1996;22(6):1026–32.PubMedCrossRefGoogle Scholar
  211. 211.
    Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008;21(3):538–82.PubMedPubMedCentralCrossRefGoogle Scholar
  212. 212.
    Levin AS, Barone AA, Penco J, Santos MV, Marinho IS, Arruda EA, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis. 1999;28(5):1008–11.PubMedCrossRefGoogle Scholar
  213. 213.
    Hogg GM, Barr JG, Webb CH. In-vitro activity of the combination of colistin and rifampicin against multidrug-resistant strains of Acinetobacter baumannii. J Antimicrob Chemother. 1998;41(4):494–5.PubMedCrossRefGoogle Scholar
  214. 214.
    Henwood CJ, Gatward T, Warner M, James D, Stockdale MW, Spence RP, et al. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J Antimicrob Chemother. 2002;49(3):479–87.PubMedCrossRefGoogle Scholar
  215. 215.
    Anthony KB, Fishman NO, Linkin DR, Gasink LB, Edelstein PH, Lautenbach E. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis. 2008;46(4):567–70.PubMedCrossRefGoogle Scholar
  216. 216.
    Peleg AY, Potoski BA, Rea R, Adams J, Sethi J, Capitano B, et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother. 2007;59(1):128–31.PubMedCrossRefGoogle Scholar
  217. 217.
    Schafer JJ, Goff DA, Stevenson KB, Mangino JE. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii. Pharmacotherapy. 2007;27(7):980–7.PubMedCrossRefGoogle Scholar
  218. 218.
    Navon-Venezia S, Leavitt A, Carmeli Y. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother. 2007;59(4):772–4.PubMedCrossRefGoogle Scholar
  219. 219.
    Falagas ME, Maraki S, Karageorgopoulos DE, Kastoris AC, Mavromanolakis E, Samonis G. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. Int J Antimicrob Agents. 2010;35(3):240–3.PubMedCrossRefGoogle Scholar
  220. 220.
    Giamarellou H. Multidrug-resistant gram-negative bacteria: how to treat and for how long. Int J Antimicrob Agents. 2010;36 Suppl 2:S50–4.PubMedCrossRefGoogle Scholar
  221. 221.
    Averbuch D, Cordonnier C, Livermore DM, Mikulska M, Orasch C, Viscoli C, et al. Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011). Haematologica. 2013;98(12):1836–47.PubMedPubMedCentralCrossRefGoogle Scholar
  222. 222.
    Durakovic N, Radojcic V, Boban A, Mrsic M, Sertic D, Serventi-Seiwerth R, et al. Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis. Intern Med. 2011;50(9):1009–13.PubMedCrossRefGoogle Scholar
  223. 223.
    Hachem RY, Chemaly RF, Ahmar CA, Jiang Y, Boktour MR, Rjaili GA, et al. Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients. Antimicrob Agents Chemother. 2007;51(6):1905–11.PubMedPubMedCentralCrossRefGoogle Scholar
  224. 224.
    Mostardeiro MM, Pereira CA, Marra AR, Pestana JO, Camargo LF. Nephrotoxicity and efficacy assessment of polymyxin use in 92 transplant patients. Antimicrob Agents Chemother. 2013;57(3):1442–6.PubMedPubMedCentralCrossRefGoogle Scholar
  225. 225.
    Tumbarello M, De Pascale G, Trecarichi EM, De Martino S, Bello G, Maviglia R, et al. Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible gram-negative bacteria. Chest. 2013;144(6):1768–75.PubMedCrossRefGoogle Scholar
  226. 226.
    Segal-Maurer S, Mariano N, Qavi A, Urban C, Rahal Jr JJ. Successful treatment of ceftazidime-resistant Klebsiella pneumoniae ventriculitis with intravenous meropenem and intraventricular polymyxin B: case report and review. Clin Infect Dis. 1999;28(5):1134–8.PubMedCrossRefGoogle Scholar
  227. 227.
    Novelli G, Morabito V, Ferretti G, Poli L, Novelli S, Ruberto F, et al. Safety of polymyxin-B-based hemoperfusion in kidney and liver transplant recipients. Transplant Proc. 2012;44(7):1966–72.PubMedCrossRefGoogle Scholar
  228. 228.
    Suhling H, Rademacher J, Greer M, Haverich A, Warnecke G, Gottlieb J, et al. Inhaled colistin following lung transplantation in colonised cystic fibrosis patients. Eur Respir J. 2013;42(2):542–4.PubMedCrossRefGoogle Scholar
  229. 229.
    Paul M, Bishara J, Levcovich A, Chowers M, Goldberg E, Singer P, et al. Effectiveness and safety of colistin: prospective comparative cohort study. J Antimicrob Chemother. 2010;65(5):1019–27.PubMedCrossRefGoogle Scholar
  230. 230.
    Yahav D, Farbman L, Leibovici L, Paul M. Colistin: new lessons on an old antibiotic. Clin Microbiol Infect. 2012;18(1):18–29.PubMedCrossRefGoogle Scholar
  231. 231.
    Falagas ME, Rafailidis PI, Ioannidou E, Alexiou VG, Matthaiou DK, Karageorgopoulos DE, et al. Colistin therapy for microbiologically documented multidrug-resistant gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents. 2010;35(2):194–9.PubMedCrossRefGoogle Scholar
  232. 232.
    Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care. 2006;10(1):R27.PubMedPubMedCentralCrossRefGoogle Scholar
  233. 233.
  234. 234.
    Beno P, Krcmery V, Demitrovicova A. Bacteraemia in cancer patients caused by colistin-resistant gram-negative bacilli after previous exposure to ciprofloxacin and/or colistin. Clin Microbiol Infect. 2006;12(5):497–8.PubMedCrossRefGoogle Scholar
  235. 235.
    Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011;55(7):3284–94.PubMedPubMedCentralCrossRefGoogle Scholar
  236. 236.
    Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother. 2009;53(8):3430–6.PubMedPubMedCentralCrossRefGoogle Scholar
  237. 237.
    Dalfino L, Puntillo F, Mosca A, Monno R, Spada ML, Coppolecchia S, et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis. 2012;54(12):1720–6.PubMedPubMedCentralCrossRefGoogle Scholar
  238. 238.
    Cai Y, Wang R, Liang B, Bai N, Liu Y. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother. 2011;55(3):1162–72.PubMedCrossRefGoogle Scholar
  239. 239.
    Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother. 2010;65(6):1119–25.PubMedCrossRefGoogle Scholar
  240. 240.
    Neonakis IK, Spandidos DA, Petinaki E. Confronting multidrug-resistant Acinetobacter baumannii: a review. Int J Antimicrob Agents. 2011;37(2):102–9.PubMedCrossRefGoogle Scholar
  241. 241.
    Chemaly RF, Hanmod SS, Jiang Y, Rathod DB, Mulanovich V, Adachi JA, et al. Tigecycline use in cancer patients with serious infections: a report on 110 cases from a single institution. Medicine. 2009;88(4):211–20.PubMedCrossRefGoogle Scholar
  242. 242.
    Bassetti M, Nicolini L, Repetto E, Righi E, Del Bono V, Viscoli C. Tigecycline use in serious nosocomial infections: a drug use evaluation. BMC Infect Dis. 2010;10:287.PubMedPubMedCentralCrossRefGoogle Scholar
  243. 243.
    Mouloudi E, Massa E, Piperidou M, Papadopoulos S, Iosifidis E, Roilides I, et al. Tigecycline for treatment of carbapenem-resistant Klebsiella pneumoniae infections after liver transplantation in the intensive care unit: a 3-year study. Transplant Proc. 2014;46(9):3219–21.PubMedCrossRefGoogle Scholar
  244. 244.
    Arpin C, Labia R, Andre C, Frigo C, El Harrif Z, Quentin C. SHV-16, a beta-lactamase with a pentapeptide duplication in the omega loop. Antimicrob Agents Chemother. 2001;45(9):2480–5.PubMedPubMedCentralCrossRefGoogle Scholar
  245. 245.
    Rodriguez-Avial C, Rodriguez-Avial I, Merino P, Picazo JJ. Klebsiella pneumoniae: development of a mixed population of carbapenem and tigecycline resistance during antimicrobial therapy in a kidney transplant patient. Clin Microbiol Infect. 2012;18(1):61–6.PubMedCrossRefGoogle Scholar
  246. 246.
    Nilsson AI, Berg OG, Aspevall O, Kahlmeter G, Andersson DI. Biological costs and mechanisms of fosfomycin resistance in Escherichia coli. Antimicrob Agents Chemother. 2003;47(9):2850–8.PubMedPubMedCentralCrossRefGoogle Scholar
  247. 247.
    Hasegawa S, Horibe K, Kawabe T, Kato K, Kojima S, Matsuyama T, et al. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in children with hematologic malignancies: incidence, onset time and risk factors. Bone Marrow Transplant. 1998;22(12):1191–7.PubMedCrossRefGoogle Scholar
  248. 248.
    Reid GE, Grim SA, Layden JE, Akkina S, Tang I, Campara M, et al. The use of fosfomycin to treat urinary tract infections in kidney transplant recipients. Transplantation. 2013;96(3):e12–4.PubMedCrossRefGoogle Scholar
  249. 249.
    Neuner EA, Sekeres J, Hall GS, van Duin D. Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms. Antimicrob Agents Chemother. 2012;56(11):5744–8.PubMedPubMedCentralCrossRefGoogle Scholar
  250. 250.
    Elemam A, Rahimian J, Doymaz M. In vitro evaluation of antibiotic synergy for polymyxin B-resistant carbapenemase-producing Klebsiella pneumoniae. J Clin Microbiol. 2010;48(10):3558–62.PubMedPubMedCentralCrossRefGoogle Scholar
  251. 251.
    Souli M, Galani I, Boukovalas S, Gourgoulis MG, Chryssouli Z, Kanellakopoulou K, et al. In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development. Antimicrob Agents Chemother. 2011;55(5):2395–7.PubMedPubMedCentralCrossRefGoogle Scholar
  252. 252.
    Bulik CC, Nicolau DP. Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2011;55(6):3002–4.PubMedPubMedCentralCrossRefGoogle Scholar
  253. 253.
    Zusman O, Avni T, Leibovici L, Adler A, Friberg L, Stergiopoulou T, et al. Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. Antimicrob Agents Chemother. 2013;57(10):5104–11.PubMedPubMedCentralCrossRefGoogle Scholar
  254. 254.
    Rahal JJ. Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis. 2006;43 Suppl 2:S95–9.PubMedCrossRefGoogle Scholar
  255. 255.
    Tripodi MF, Durante-Mangoni E, Fortunato R, Utili R, Zarrilli R. Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases. Int J Antimicrob Agents. 2007;30(6):537–40.PubMedCrossRefGoogle Scholar
  256. 256.
    Tascini C, Ferranti S, Messina F, Menichetti F. In vitro and in vivo synergistic activity of colistin, rifampin, and amikacin against a multiresistant Pseudomonas aeruginosa isolate. Clin Microbiol Infect. 2000;6(12):690–1.PubMedCrossRefGoogle Scholar
  257. 257.
    Rynn C, Wootton M, Bowker KE, Alan Holt H, Reeves DS. In vitro assessment of colistin’s antipseudomonal antimicrobial interactions with other antibiotics. Clin Microbiol Infect. 1999;5(1):32–6.PubMedCrossRefGoogle Scholar
  258. 258.
    Stanzani M, Tumietto F, Giannini MB, Bianchi G, Nanetti A, Vianelli N, et al. Successful treatment of multi-resistant Pseudomonas aeruginosa osteomyelitis after allogeneic bone marrow transplantation with a combination of colistin and tigecycline. J Med Microbiol. 2007;56(Pt 12):1692–5.PubMedCrossRefGoogle Scholar
  259. 259.
    Marcus R, Paul M, Elphick H, Leibovici L. Clinical implications of beta-lactam-aminoglycoside synergism: systematic review of randomised trials. Int J Antimicrob Agents. 2011;37(6):491–503.PubMedCrossRefGoogle Scholar
  260. 260.
    Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis. 2004;4(8):519–27.PubMedCrossRefGoogle Scholar
  261. 261.
    Bucaneve G, Micozzi A, Picardi M, Ballanti S, Cascavilla N, Salutari P, et al. Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia. J Clin Oncol. 2014;32(14):1463–71.PubMedCrossRefGoogle Scholar
  262. 262.
    Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55(7):943–50.PubMedCrossRefGoogle Scholar
  263. 263.
    Micek ST, Welch EC, Khan J, Pervez M, Doherty JA, Reichley RM, et al. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to gram-negative bacteria: a retrospective analysis. Antimicrob Agents Chemother. 2010;54(5):1742–8.PubMedPubMedCentralCrossRefGoogle Scholar
  264. 264.
    Bass SN, Bauer SR, Neuner EA, Lam SW. Mortality risk factors for critically ill patients with carbapenem-resistant bacteremia: impact of combination antimicrobial therapy. Antimicrob Agents Chemother. 2015.Google Scholar
  265. 265.
    Bassetti M, Repetto E, Righi E, Boni S, Diverio M, Molinari MP, et al. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother. 2008;61(2):417–20.PubMedCrossRefGoogle Scholar
  266. 266.
    Cirioni O, Ghiselli R, Orlando F, Silvestri C, Mocchegiani F, Rocchi M, et al. Efficacy of colistin/rifampin combination in experimental rat models of sepsis due to a multiresistant Pseudomonas aeruginosa strain. Crit Care Med. 2007;35(7):1717–23.PubMedCrossRefGoogle Scholar
  267. 267.
    Giamarellos-Bourboulis EJ, Sambatakou H, Galani I, Giamarellou H. In vitro interaction of colistin and rifampin on multidrug-resistant Pseudomonas aeruginosa. J Chemother. 2003;15(3):235–8.PubMedCrossRefGoogle Scholar
  268. 268.
    Durante-Mangoni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, Murino P, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis. 2013;57(3):349–58.PubMedCrossRefGoogle Scholar
  269. 269.
    Aydemir H, Akduman D, Piskin N, Comert F, Horuz E, Terzi A, et al. Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol Infect. 2013;141(6):1214–22.PubMedCrossRefGoogle Scholar
  270. 270.
    Paul M, Carmeli Y, Durante-Mangoni E, Mouton JW, Tacconelli E, Theuretzbacher U, et al. Combination therapy for carbapenem-resistant gram-negative bacteria. J Antimicrob Chemother. 2014;69(9):2305–9.PubMedCrossRefGoogle Scholar
  271. 271.
    Hamer DH. Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin. Am J Respir Crit Care Med. 2000;162(1):328–30.PubMedCrossRefGoogle Scholar
  272. 272.
    Feeley TW, Du Moulin GC, Hedley-Whyte J, Bushnell LS, Gilbert JP, Feingold DS. Aerosol polymyxin and pneumonia in seriously ill patients. N Engl J Med. 1975;293(10):471–5.PubMedCrossRefGoogle Scholar
  273. 273.
    Gafter-Gvili A, Fraser A, Paul M, Vidal L, Lawrie TA, van de Wetering MD, et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev. 2012;1:CD004386.PubMedPubMedCentralGoogle Scholar
  274. 274.
    Ng ES, Liew Y, Earnest A, Koh LP, Lim SW, Hsu LY. Audit of fluoroquinolone prophylaxis against chemotherapy-induced febrile neutropenia in a hospital with highly prevalent fluoroquinolone resistance. Leukemia Lymphoma. 2011;52(1):131–3.PubMedCrossRefGoogle Scholar
  275. 275.
    Lingaratnam S, Thursky KA, Slavin MA. Fluoroquinolone prophylaxis: a word of caution. Leukemia Lymphoma. 2011;52(1):5–6.PubMedCrossRefGoogle Scholar
  276. 276.
    Gafter-Gvili A, Paul M, Fraser A, Leibovici L. Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis. J Antimicrob Chemother. 2007;59(1):5–22.PubMedCrossRefGoogle Scholar
  277. 277.
    Garnica M, Nouer SA, Pellegrino FL, Moreira BM, Maiolino A, Nucci M. Ciprofloxacin prophylaxis in high risk neutropenic patients: effects on outcomes, antimicrobial therapy and resistance. BMC Infect Dis. 2013;13(1):356.PubMedPubMedCentralCrossRefGoogle Scholar
  278. 278.
    Rangaraj G, Granwehr BP, Jiang Y, Hachem R, Raad I. Perils of quinolone exposure in cancer patients: breakthrough bacteremia with multidrug-resistant organisms. Cancer. 2010;116(4):967–73.PubMedCrossRefGoogle Scholar
  279. 279.
    Averbuch D, Orasch C, Cordonnier C, Livermore DM, Mikulska M, Viscoli C, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica. 2013;98(12):1826–35.PubMedPubMedCentralCrossRefGoogle Scholar
  280. 280.
    Orasch C, Averbuch D, Mikulska M, Cordonnier C, Livermore DM, Gyssens IC, et al. Discontinuation of empirical antibiotic therapy in neutropenic leukaemia patients with fever of unknown origin is ethical. Clin Microbiol Infect. 2015;21(3):e25–7.PubMedCrossRefGoogle Scholar
  281. 281.
    Garcia-Fernandez S, Morosini MI, Marco F, Gijon D, Vergara A, Vila J, et al. Evaluation of the eazyplex(R) SuperBug CRE system for rapid detection of carbapenemases and ESBLs in clinical Enterobacteriaceae isolates recovered at two Spanish hospitals. J Antimicrob Chemother. 2015;70(4):1047–50.PubMedGoogle Scholar
  282. 282.
    Dortet L, Brechard L, Poirel L, Nordmann P. Rapid detection of carbapenemase-producing Enterobacteriaceae from blood cultures. Clin Microbiol Infect. 2014;20(4):340–4.PubMedCrossRefGoogle Scholar
  283. 283.
    Dortet L, Poirel L, Nordmann P. Rapid detection of ESBL-producing Enterobacteriaceae in blood cultures. Emerg Infect Dis. 2015;21(3):504–7.PubMedPubMedCentralCrossRefGoogle Scholar
  284. 284.
    Huang TD, Berhin C, Bogaerts P, Glupczynski Y. Comparative evaluation of two chromogenic tests for rapid detection of carbapenemase in Enterobacteriaceae and in Pseudomonas aeruginosa isolates. J Clin Microbiol. 2014;52(8):3060–3.PubMedPubMedCentralCrossRefGoogle Scholar
  285. 285.
    Dortet L, Brechard L, Cuzon G, Poirel L, Nordmann P. Strategy for rapid detection of carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2014;58(4):2441–5.PubMedPubMedCentralCrossRefGoogle Scholar
  286. 286.
    Johansson A, Ekelof J, Giske CG, Sundqvist M. The detection and verification of carbapenemases using ertapenem and matrix assisted laser desorption ionization-time of flight. BMC Microbiol. 2014;14:89.PubMedPubMedCentralCrossRefGoogle Scholar
  287. 287.
    Tverdek FP, Rolston KV, Chemaly RF. Antimicrobial stewardship in patients with cancer. Pharmacotherapy. 2012;32(8):722–34.PubMedCrossRefGoogle Scholar
  288. 288.
    Gyssens IC, Kern WV, Livermore DM. The role of antibiotic stewardship in limiting antibacterial resistance among hematology patients. Haematologica. 2013;98(12):1821–5.PubMedPubMedCentralCrossRefGoogle Scholar
  289. 289.
    Eisen D, Russell EG, Tymms M, Roper EJ, Grayson ML, Turnidge J. Random amplified polymorphic DNA and plasmid analyses used in investigation of an outbreak of multiresistant Klebsiella pneumoniae. J Clin Microbiol. 1995;33(3):713–7.PubMedPubMedCentralGoogle Scholar
  290. 290.
    Royle J, Halasz S, Eagles G, Gilbert G, Dalton D, Jelfs P, et al. Outbreak of extended spectrum beta lactamase producing Klebsiella pneumoniae in a neonatal unit. Arch Dis Child Fetal Neonatal Ed. 1999;80(1):F64–8.PubMedPubMedCentralCrossRefGoogle Scholar
  291. 291.
    Munoz-Price LS, Quinn JP. Deconstructing the infection control bundles for the containment of carbapenem-resistant Enterobacteriaceae. Curr Opin Infect Dis. 2013;26(4):378–87.PubMedCrossRefGoogle Scholar
  292. 292.
    Kallen A, Guh A. United States Centers for Disease Control and Prevention issue updated guidance for tackling carbapenem-resistant enterobacteriaceae. Euro Surveill. 2012;17(26). pii: 20207.Google Scholar
  293. 293.
    Tacconelli E, Peschel A, Autenrieth IB. Translational research strategy: an essential approach to fight the spread of antimicrobial resistance. J Antimicrob Chemother. 2014;69(11):2889–91.PubMedCrossRefGoogle Scholar
  294. 294.
    Weiss J, Arielly H, Ganor N, Paitan Y. Evaluation of the NanoCHIP Infection Control Panel test for direct detection and screening of methicillin-resistant Staphylococcus aureus (MRSA), Klebsiella pneumoniae carbapenemase (KPC)-producing bacteria and vancomycin-resistant Enterococcus (VRE). Infection. 2015.Google Scholar
  295. 295.
    Vasoo S, Cunningham SA, Kohner PC, Mandrekar JN, Lolans K, Hayden MK, et al. Rapid and direct real-time detection of blaKPC and blaNDM from surveillance samples. J Clin Microbiol. 2013;51(11):3609–15.PubMedPubMedCentralCrossRefGoogle Scholar
  296. 296.
    Oren I, Sprecher H, Finkelstein R, Hadad S, Neuberger A, Hussein K, et al. Eradication of carbapenem-resistant Enterobacteriaceae gastrointestinal colonization with nonabsorbable oral antibiotic treatment: a prospective controlled trial. Am J Infect Control. 2013;41(12):1167–72.PubMedCrossRefGoogle Scholar
  297. 297.
    Tascini C, Sbrana F, Flammini S, Tagliaferri E, Arena F, Leonildi A, et al. Oral gentamicin gut decontamination for prevention of KPC-producing Klebsiella pneumoniae infections: relevance of concomitant systemic antibiotic therapy. Antimicrob Agents Chemother. 2014;58(4):1972–6.PubMedPubMedCentralCrossRefGoogle Scholar
  298. 298.
    Oostdijk EA, Kesecioglu J, Schultz MJ, Visser CE, de Jonge E, van Essen EH, et al. Effects of decontamination of the oropharynx and intestinal tract on antibiotic resistance in ICUs: a randomized clinical trial. JAMA. 2014;312(14):1429–37.PubMedCrossRefGoogle Scholar
  299. 299.
    Lubbert C, Faucheux S, Becker-Rux D, Laudi S, Durrbeck A, Busch T, et al. Rapid emergence of secondary resistance to gentamicin and colistin following selective digestive decontamination in patients with KPC-2-producing Klebsiella pneumoniae: a single-centre experience. Int J Antimicrob Agents. 2013;42(6):565–70.PubMedCrossRefGoogle Scholar
  300. 300.
    Saidel-Odes L, Polachek H, Peled N, Riesenberg K, Schlaeffer F, Trabelsi Y, et al. A randomized, double-blind, placebo-controlled trial of selective digestive decontamination using oral gentamicin and oral polymyxin E for eradication of carbapenem-resistant Klebsiella pneumoniae carriage. Infect Control Hosp Epidemiol. 2012;33(1):14–9.PubMedCrossRefGoogle Scholar
  301. 301.
    Zuckerman T, Benyamini N, Sprecher H, Fineman R, Finkelstein R, Rowe JM, et al. SCT in patients with carbapenem resistant Klebsiella pneumoniae: a single center experience with oral gentamicin for the eradication of carrier state. Bone Marrow Transplant. 2011;46(9):1226–30.PubMedCrossRefGoogle Scholar
  302. 302.
    Giani T, Conte V, Mandala S, D'Andrea MM, Luzzaro F, Conaldi PG, et al. Cross-infection of solid organ transplant recipients by a multidrug-resistant Klebsiella pneumoniae isolate producing the OXA-48 carbapenemase, likely derived from a multiorgan donor. J Clin Microbiol. 2014;52(7):2702–5.PubMedPubMedCentralCrossRefGoogle Scholar
  303. 303.
    Goldberg E, Bishara J, Lev S, Singer P, Cohen J. Organ transplantation from a donor colonized with a multidrug-resistant organism: a case report. Transpl Infect Dis. 2012;14(3):296–9.PubMedCrossRefGoogle Scholar
  304. 304.
    Bishara J, Goldberg E, Lev S, Singer P, Ashkenazi T, Cohen J. The utilization of solid organs for transplantation in the setting of infection with multidrug-resistant organisms: an expert opinion. Clin Transpl. 2012;26(6):811–5.CrossRefGoogle Scholar
  305. 305.
    Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother. 1999;33(9):960–7.PubMedCrossRefGoogle Scholar
  306. 306.
    Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis. 2005;41 Suppl 5:S303–14.PubMedCrossRefGoogle Scholar
  307. 307.
    Apisarnthanarak A, Mundy LM. Use of high-dose 4-h infusion of doripenem, in combination with fosfomycin, for treatment of carbapenem-resistant Pseudomonas aeruginosa pneumonia. Clin Infect Dis. 2010;51(11):1352–4.PubMedCrossRefGoogle Scholar
  308. 308.
    Falagas ME, Roussos N, Gkegkes ID, Rafailidis PI, Karageorgopoulos DE. Fosfomycin for the treatment of infections caused by gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies. Expert Opin Investig Drugs. 2009;18(7):921–44.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Open Access This chapter is distributed under the terms of the Creative Commons Attribution Noncommercial License, which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Authors and Affiliations

  1. 1.Pediatric Infectious Diseases UnitHadassah Hebrew University Medical CenterJerusalemIsrael

Personalised recommendations